Background
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder that progresses over time, and currently it is the fourth leading cause of death across the globe. The World Health Organization (WHO) predicts that the disease will become the third leading cause of death by 2030. The present study aimed to assess the burden trends of COPD in Iran by estimating the disability-adjusted life years (DALYs) from 1995 to 2015.
Methods
Data were retrospectively collected as the Global Burden of Disease (GBD) from 1995 to 2015 and published by the Institute for Health Metrics and Evaluation. We applied DALYs, incidence and prevalence rate to report the burden of COPD in Iran. To assess the statistical significance according to trend, the Cochran-Armitage test was applied. Additionally, the t-test was used to analyze the DALYs number by gender and Onaway ANOVA by age groups at a significance level set atP < 0.05.
Results
From 1995 to 2015, there were approximately 1.1 million DALYs attributable to COPD in Iran. In both genders and at all ages, the number of DALYs increased significantly from 176,224 in 1995 to 253,618 in 2015. The incidence and prevalence rate were 76.65 and 1491.37 per 100,000 population, respectively in both genders in 2015 in Iran. It is noticeable that the number of deaths during the study years, 1995 to 2015, was 39,064. This study showed that the COPD burden was significantly different by age groups and gender.
Conclusions
COPD is still a public health problem in Iran and has an increasing trend. The majority of DALYs were due to the years of life lost as a result of premature death (YLLs), indicating that prevention and early detection, especially in the age groups of 15 to 70 years, should be considered.
Background: Drug use has always been suggested as the first preventable agent of various diseases and deaths around the world. Nowadays, this problem is more prevalent among young people and students of universities that are at risk. Objectives: Due to the newness of the case and legal restrictions on the consumption of psychoactive drugs in Iran, there are no statistics regarding the prevalence of consuming these drugs; therefore, it was decided to determine the prevalence and causes of tendency towards the consumption of psychoactive drugs among students of Yazd Shahid Sadoughi University of Medical Sciences. Methods: The present research was a cross sectional study, through which 250 students of Yazd University of Medical Sciences were selected using systematic random sampling and investigated in 2015. Data was collected through a self-made questionnaire and then analyzed using the SPSS software version 22 at a significance level of P = 0.05 using frequency tables, chart, Chi-square, and logistic regression test. Results: The prevalence of psychoactive drugs consumption was 5.6%. The most important factor of tendency towards consumption of psychoactive drugs among students has been failure to meet their emotional needs (35.7%), yet taking pleasure has been the mainspring for consuming these drugs in most cases (50%). There was a statistical significant relationship between psychoactive drugs consumption and age, place of residence, drug history in parents, and being exposed to cigarette smoke throughout the day (P < 0.05). The most commonly estimated odds ratio (OR = 13.08) was related to non-native students. Conclusions: Due to the relatively high prevalence of psychoactive drugs consumption in students of medical sciences as messengers of health, holding life skill workshops and consulting with students, providing appropriate recreational facilities seem essential in order to reduce the prevalence and prevent this dilemma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.